Endosleeve and Ozempic

New research was presented at Digestive Disease Week® 2021 suggests the glucagon-like peptide-1 receptor agonist (GLP-1) semaglutide is a safe and effective adjunct to endoscopic sleeve gastroplasty (ESG). In fact, the analog could help patients undergoing ESG achieve weight loss comparable to that seen with the highly successful but far more invasive laparoscopic sleeve gastrectomy (LSG).
Dr. Hoff’s presentation at DDW of Semaglutide in association to endoscopic sleeve gastroplasty will take endoscopic bariatric procedures outcomes to the next level.
Literature
Badurdeen D, Hoff AC, Hedjoudje A, Adam A, Itani MI, Farha J, Abbarh S, Kalloo AN, Khashab MA, Singh VK, Oberbach A, Neto MG, Barrichello S, Kumbhari V. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2021 Jun;93(6):1316-1324.e1. doi: 10.1016/j.gie.2020.10.016.
Epub 2020 Oct 17. PMID: 33075366.